Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes

A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelsson, Stina, Chéramy, Mikael, Hjorth, Maria, Pihl, Mikael, Åkerman, Linda, Martinuzzi, Emanuela, Mallone, Roberto, Ludvigsson, Johnny, Casas, Rosaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236224/
https://www.ncbi.nlm.nih.gov/pubmed/22174945
http://dx.doi.org/10.1371/journal.pone.0029008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236224/
https://www.ncbi.nlm.nih.gov/pubmed/22174945
http://dx.doi.org/10.1371/journal.pone.0029008

Ejemplares similares